Frequency: Quarterly

Location: Quarterly Financial Statement



TABLE 2: CAPITAL STRUCTURE - MARCH 2023

Balance sheet - Step 1 (Table 2(b))

All figures are in SAR'000

All ligures are in SAN 000	Balance sheet in Published financial statements (C)	Adjustment of banking associates / other entities (*)	Under regulatory scope of consolidation (E)
Assets			
Cash and balances at central banks	14,066,828		14,066,828
Due from banks and other financial institutions	4,753,813		4,753,813
Investments, net	41,788,256		41,788,256
Loans and advances, net	144,727,221		144,727,221
Debt securities	0		0
Trading assets	0		0
Investment in associates	982,685		982,685
Derivatives	2,405,786		2,405,786
Investment property	0		0
Other real estate	1,268,150		1,268,150
Property and equipment, net	2,260,224		2,260,224
Other assets	1,789,481		1,789,481
Total assets	214,042,444	0	214,042,444
Liabilities Due to Banks and other financial institutions	13,660,174		13,660,174
Items in the course of collection due to other banks	0		0
Customer deposits	155,247,260		155,247,260
Trading liabilities	0		0
Local sukuk issued	2,852,524		2,852,524
Derivatives	1,755,246		1,755,246
Retirement benefit liabilities	567,550		567,550
Taxation liabilities	686,012		686,012
Accruals and deferred income	0		0
Other liabilities and accruals	6,605,653		6,605,653
Subtotal	181,374,419	0	181,374,419
Paid up share capital	15,000,000		15,000,000
Statutory reserves	9,630,000		9,630,000
Other reserves	127,312		127,312
Retained earnings	7,886,828		7,886,828
Minority Interest	23,885		23,885
Proposed dividends	0		0
Total liabilities and equity	214,042,444	0	214,042,444

Frequency: Quarterly

Location: Quarterly Financial Statement



TABLE 2: CAPITAL STRUCTURE - MARCH 2023

Balance sheet - Step 2 (Table 2(c))

All figures are in SAR'000

All ligures are in SAIN 000	Balance sheet in Published financial statements (C)	Adjustment of banking associates / other entities (D)	Under regulatory scope of consolidation (E)	Reference
<u>Assets</u>				
Cash and balances at central banks	14,066,828		14,066,828	
Due from banks and other financial institutions	4,753,813		4,753,813	
Investments, net	41,788,256		41,788,256	
Loans and advances, net of which Collective provisions	144,727,221 1,229,526		144,727,221 1,229,526	A
Debt securities	1,229,320		1,229,326	^
Trading assets	0		0	
Investment in associates	982,685		982,685	
Derivatives	2,405,786		2,405,786	
Investment property	0		0	
Other real estate	1,268,150		1,268,150	
Property and equipment, net	2,260,224		2,260,224	
Other assets	1,789,481		1,789,481	
Total assets	214,042,444	0	214,042,444	
<u>Liabilities</u> Due to Banks and other financial institutions	13,660,174		13,660,174	
Items in the course of collection due to other banks	0		0	
Customer deposits	155,247,260		155,247,260	
Trading liabilities Local sukuk issued	0 2,852,524		2,852,524	
of which Tier 2 capital instruments	2,812,500		2,812,500	В
Derivatives	1,755,246		1,755,246	В
Retirement benefit liabilities	567,550		567,550	
Taxation liabilities	686,012		686,012	
Accruals and deferred income	000,012		000,012	
Borrowings	0		0	
Other liabilities and accruals	6,605,653		6,605,653	
Subtotal	181,374,419	0	181,374,419	
Paid up share capital	15,000,000		15,000,000	
of which amount eligible for CET1	15,000,000		15,000,000	н
of which amount eligible for AT1	0		0	
Statutory reserves	9,630,000		9,630,000	G
Other reserves	127,312		127,312	Ċ
Retained earnings	7,886,828	0	7,886,828	Ĵ
SAMA supervisory provision adjustment	0	Ü	.,555,626	-
Minority Interest	23,885		23,885	
Proposed dividends	0		0	
Total liabilities and equity	214,042,444	0	214,042,444	

Frequency: Quarterly
Location: Quarterly Financial Statement



TABLE 2: CAPITAL STRUCTURE - MARCH 2023

Common template (transition) - Step 3 (Table 2(d)) i

(From January 2013 to 2018 identical to post 2018) With amount subject to Pre- Basel III Treatment
All figures are in SAR'000

Components¹ of regulatory capital reported by the bank

Source based on reference numbers / letters of the Amounts¹ balance sheet subject to under the Pre - regulatory scope Basel III treatment from step 2

H G+J+IFRS9 Adj C

(0)		bank	treatment	fro
(2)	Common Equity Tier 1 capital: Instruments and reserves			
1	Directly issued qualifying common share capital (and equivalent for non-joint stock companies) plus			
·	related stock surplus	15,000,000		
2	Retained earnings	17,700,589		G
3	Accumulated other comprehensive income (and other reserves)	127,312		
4	Directly issued capital subject to phase out from CET1 (only applicable to non-joint stock companies)			
5	Common share capital isued by subsidiaries and held by third parties (amount allowed in group		ļ	Ī
_	CET1)	22 027 004	L	J
6	Common Equity Tier 1 capital before regulatory adjustments Common Equity Tier 1 capital: Regulatory adjustments	32,827,901		
7	Prudential valuation adjustments		Г	7
	Goodwill (net of related tax liability)		<u> </u>	
	Other intangibles other than mortgage-servicing rights (net of related tax liability)		<u> </u>]
10	Deferred tax assets that rely on future profitability excluding those arising from temporary differences (net of related tax liability)]
11	Cash-flow hedge reserve]
	Shortfall of provisions to expected losses			
	Securitisation gain on sale (as set out in paragraph 562 of Basel II framework)		L	į
	Gains and losses due to changes in own credit risk on fair valued liabilities		j	i
	Defined-benefit pension fund net assets		<u> </u>	i
	Investments in own shares (if not already netted off paid-in capital on reported balance sheet) Reciprocal cross-holdings in common equity		}	4
			ļ	1
10	Investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of the issued share capital (amount above 10% threshold)		İ	į
10	,		}	1
19	Significant investments in the common stock of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of eligible short positions (amount above 10% threshold)			
20	Mortgage servicing rights (amount above 10% threshold)			i
	Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related		}	1
۷ ۱	tax liability)		ļ	ļ
22	Amount exceeding the 15% threshold		h	1
23	of which: significant investments in the common stock of financials		T	i
24	of which: mortgage servicing rights			
25	of which: deferred tax assets arising from temporary differences]
26	National specific regulatory adjustments		<u> </u>	_
	REGULATORY ADJUSTMENTS APPLIED TO COMMON EQUITY TIER 1 IN RESPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT			
لإ	OF WHICH: [INSERT NAME OF ADJUSTMENT]	ļi		
07	OF WHICH:			
	Regulatory adjustments applied to Common Equity Tier 1 due to insufficient Additional Tier 1 and Tier 2 to cover deductions			
	Total regulatory adjustments to Common equity Tier 1			
29	Common Equity Tier 1 capital (CET1)	32,827,901		
20	Additional Tier 1 capital: instruments			
31	Directly issued qualifying Additional Tier 1 instruments plus related stock surplus of which: classified as equity under applicable accounting standards			
32	of which: classified as liabilities under applicable accounting standards			
	Directly issued capital instruments subject to phase out from Additional Tier 1			
	Additional Tier 1 instruments (and CET1 instruments not included in row 5) issued by subsidiaries			
	and held by third parties (amount allowed in group AT1)			
	of which: instruments issued by subsidiaries subject to phase out			
36	Additional Tier 1 capital before regulatory adjustments			
07	Additional Tier 1 capital: regulatory adjustments			
Ů.	Investments in own Additional Tier 1 instruments		⊢	4
	Reciprocal cross-holdings in Additional Tier 1 instruments Investments in the capital of banking, financial and insurance entities that are outside the scope of			i
39	regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of the issued common share capital of the entity (amount above 10% threshold)			i
40	Significant investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation (net of eligible short positions)			<u> </u>
41	National specific regulatory adjustments			-
	REGULATORY ADJUSTMENTS APPLIED TO ADDITIONAL TIER 1 IN RESPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT			
<u> </u>	OF WHICH: [INSERT NAME OF ADJUSTMENT] OF WHICH:			
42	Regulatory adjustments applied to Additional Tier 1 due to insufficient Tier 2 to cover deductions	 		
	Total regulatory adjustments to Additional Tier 1 capital			
44	Additional Tier 1 capital (AT1)			
45	Tier 1 capital (T1 = CET1 + AT1)	32,827,901		
		,- ,		

Frequency: Quarterly

Location: Quarterly Financial Statement



TABLE 2: CAPITAL STRUCTURE - MARCH 2023

Common template (transition) - Step 3 (Table 2(d)) ii

(From January 2013 to 2018 identical to post 2018) With amount subject to Pre- Basel III Treatment

All figures are in SAR'000

Components¹ of regulatory capital reported by the bank

Source pased on reference numbers / letters of the balance sheet under the

Amounts¹ subject to Pre -Basel III treatment

regulatory scope of consolidation from step 2

	Tier 2 capital: instruments and provisions	
46	Directly issued qualifying Tier 2 instruments plus related stock surplus	2,812,500
	Directly issued capital instruments subject to phase out from Tier 2	2,012,000
	Tier 2 instruments (and CET1 and AT1 instruments not included in rows 5 or 34) issued by	
	subsidiaries and held by third parties (amount allowed in group Tier 2)	
49	of which: instruments issued by subsidiaries subject to phase out	
50	Provisions	1,229,520
51	Tier 2 capital before regulatory adjustments	4,042,026
	Tier 2 capital: regulatory adjustments	
	Investments in own Tier 2 instruments	
	Reciprocal cross-holdings in Tier 2 instruments	
	Investments in the capital of banking, financial and insurance entities that are outside the scope of regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of the issued common share capital of the entity (amount above the 10% threshold)	
	Significant investments in the capital banking, financial and insurance entities that are outside the scope of regulatory consolidation (net of eligible short positions) National specific regulatory adjustments	(
30	NAUDIAN SPECIAL REGULATORY ADJUSTMENTS APPLIED TO TIER 2 IN RESPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT OF WHICH: [INSERT NAME OF ADJUSTMENT]	
	OF WHICH: INSERT NAME OF ADJUSTMENT]	
57	Total regulatory adjustments to Tier 2 capital	
	Tier 2 capital (T2)	4,042,026
59	Total capital (TC = T1 + T2)	36,869,927
	RISK WEIGHTED ASSETS IN REPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT	
	OF WHICH: [INSERT NAME OF ADJUSTMENT]	
	OF WHICH:	
60	Total risk weighted assets	167,728,199
	Capital ratios	
	Common Equity Tier 1 (as a percentage of risk weighted assets)	19.57%
	Tier 1 (as a percentage of risk weighted assets)	19.57%
	Total capital (as a percentage of risk weighted assets)	21.98%
64	Institution specific buffer requirement (minimum CET1 requirement plus capital conservation buffer plus countercyclical buffer requirements plus G-SIB buffer requirement expressed as a percentage of risk weighted assets)	7.01%
65	of which: capital conservation buffer requirement	2.50%
_	of which: bank specific countercyclical buffer requirement	0.01%
66 67	of which: G-SIB buffer requirement	0.01%
	Common Equity Tier 1 available to meet buffers (as a percentage of risk weighted assets)	12.57%
-	National minima (if different from Basel 3)	
69	National Common Equity Tier 1 minimum ratio (if different from Basel 3 minimum)	
70	National Tier 1 minimum ratio (if different from Basel 3 minimum)	
71	National total capital minimum ratio (if different from Basel 3 minimum)	
	Amounts below the thresholds for deduction (before risk weighting)	
	Non-significant investments in the capital of other financials	
	Significant investments in the common stock of financials Methods a convicing rights (not of related to villability)	
	Mortgage servicing rights (net of related tax liability) Deferred tax assets arising from temporary differences (net of related tax liability)	
13	Applicable caps on the inclusion of provisions in Tier 2	
76	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to standardised approach (prior to application of cap)	1,229,526
77	Cap on inclusion of provisions in Tier 2 under standardised approach	1,968,748
	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to internal ratings-based approach (prior to application of cap)	1,300,740
79	Cap for inclusion of provisions in Tier 2 under internal ratings-based approach	
	Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2018	
00	and 1 Jan 2022)	
	Current cap on CET1 instruments subject to phase out arrangements	
	Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)	
82	Current cap on AT1 instruments subject to phase out arrangements	
83	Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities)	
84	Current cap on T2 instruments subject to phase out arrangements	
85	Amount excluded from T2 due to cap (excess over cap after redemptions and maturities)	



Frequency: Quarterly Location: W



TABLE 2: CAPITAL STRUCTURE - MARCH 2023			
Main features template of regulatory capital instruments - (Table 2(e))			
1 Issuer	ANB Sukuk Ltd / Fully owned subs of Arab National Bank		
2 Unique identifier (eg CUSPIN, ISIN or Bloomberg identifier for private placement)	XS2250029167		
3 Governing law(s) of the instrument	English law (except for certain provisions relating to the status and subordination of the Certificates, the Purchase Agreement and any Sale/Transfer Agreement, which shall be governed by the laws of the Kingdom of Saudi Arabia)		
Means by which enforceability requirement of Section 13 of the TLAC Term 3a Sheet is achieved (for other TLAC-eligible instruments governed by foreign law)			
4 Transitional Basel III rules	N/A		
5 Post-transitional Basel III rules	Tier 2		
6 Eligible at solo/lgroup/group&solo	Solo & Group		
7 Instrument type (types to be specified by each jurisdiction)	Unsecured Subordinated Sukuk		
8 Amount recognized in regulatory capital (Currency in millions, as of most recent reporting date)	USD 750 Million		
9 Par value of instrument	USD 750 million		
10 Accounting classification	Liability- Held at Amortised Cost		
11 Original date of issuance	28-Oct-20		
12 Perpetual or dated	Dated		
13 Original maturity date	28-Oct-30		
14 Issuer call subject to prior supervisory approval	Yes		
15 Option call date, contingent call dates and redemption amount	First Call date 28th Oct 2025,		
16 Subsequent call dates if applicable	NA		
Coupons / dividends	Semi Annually		
17 Fixed or Floating dividend/coupon	Fixed Rate Re-settable		
18 Coupon rate and any related index	3.326		
19 Existence of a dividend stopper	No No		
20 Fully discretionary, partially discretionary or mandatory	Mandatory		
21 Existence of step up or other incentive to redeem	No		
22 Non cumulative or cumulative	Non-cumulative		
23 Convertible or non-convertible	Non-convertible		
	N/A		
24 If convertible, conversion trigger (s)			
25 If convertible, fully or partially	N/A		
26 If convertible, conversion rate	N/A		
27 If convertible, mandatory or optional conversion	N/A		
28 If convertible, specify instrument type convertible into	N/A		
29 If convertible, specify issuer of instrument it converts into	N/A		
30 Write-down feature	At the point of Non-viability		
31 If write-down, write-down trigger (s)	Determined by the Banking Regulator		
32 If write-down, full or partial	Determined by the Banking Regulator		
33 If write-down, permanent or temporary	Determined by the Banking Regulator		
34 If temporary writedown, description of the write-up mechanism	Determined by the Banking Regulator		
34a Type of suboridation	Unsecured		
35 Position in subordination hierarchy in liquidation (specify instrument type imm	Subordinated in right and priority of payment, to the prior payment in full of all deposit liabilities and all other unsubordinated liabilities of the Issuer except all other present and future unsecured and subordinated obligations of the Issuer which by their terms rank equally in right and priority of payment with the Instrument		
36 Non-compliant transitioned features	No		
37 If yes, specify non-compliant features	N/A		
, , , , , , , , , , , , , , , , , , ,	ı		